Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has gained considerable attention in the past couple of years due to its potential applications in both the treatment of diabetes and weight loss/metabolism. With US FDA and EMA approvals in place (Ozempic and others) and related GLP-1 agonist analogs being developed, it is crucial to understand the […]
